Patient care standards for primary mitochondrial disease: A consensus statement from the mitochondrial medicine society

Genetics in Medicine

Volumn 19, Issue 12, 2017, Pages 1-18

  Parikh, Sumit ^a   Goldstein, Amy ^b   Karaa, Amel ^c   Koenig, Mary Kay ^d   Anselm, Irina ^e   Brunel Guitton, Catherine ^f   Christodoulou, John ^g   Cohen, Bruce H ^h   Dimmock, David ⁱ   Enns, Gregory M ^j   Falk, Marni J ^k   Feigenbaum, Annette ^l,m   Frye, Richard E ⁿ   Ganesh, Jaya ^o   Griesemer, David ^p   Haas, Richard ^m,q   Horvath, Rita ^r   Korson, Mark ^s   Kruer, Michael C ^t   Mancuso, Michelangelo ^u   McCormack, Shana ^v   Raboisson, Marie Josee ^w   Reimschisel, Tyler ^x   Salvarinova, Ramona ^y   Saneto, Russell P ^z   Scaglia, Fernando ^aa   Shoffner, John ^ab   Stacpoole, Peter W ^ac   Sue, Carolyn M ^ad   Tarnopolsky, Mark ^ae   Van Karnebeek, Clara ^af,ag   Wolfe, Lynne A ^ah   Cunningham, Zarazuela Zolkipli ^v   Rahman, Shamima ^ai   Chinnery, Patrick F ^aj   more..

^a Clevel and Clinic   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h AKRON CHILDREN'S HOSPITAL   (United States)

ⁱ RADY CHILDREN S INSTITUTE FOR GENOMIC MEDICINE   (United States)

^j LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m RADY CHILDREN'S HOSPITAL   (United States)

ⁿ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^o Cooper Medical School at Rowan University ^*  (United States)

^p Levine Children s Hospital   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r NEWCASTLE UNIVERSITY   (United Kingdom)

^s Genetic Metabolic Center for Education   (United States)

^t UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^u UNIVERSITY OF PISA   (Italy)

^v CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^w UNIVERSITY OF MONTREAL   (Canada)

^x VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^y BC CHILDREN S HOSPITAL   (Canada)

^z UNIVERSITY OF WASHINGTON   (United States)

^aa TEXAS CHILDREN S HOSPITAL   (United States)

^ab Biochemical Molecular Genetics   (United States)

^ac UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^ad ROYAL NORTH SHORE HOSPITAL   (Australia)

^ae MCMASTER UNIVERSITY   (Canada)

^af UNIVERSITY OF AMSTERDAM   (Netherlands)

^ag UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ah NATIONAL INSTITUTES OF HEALTH   (United States)

^ai UNIVERSITY COLLEGE LONDON   (United Kingdom)

^aj UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Care guidelines; Consensus criteria; Delphi method; Mitochondrial disease; Treatment

Indexed keywords

ARGININE; BOTULINUM TOXIN; INFLUENZA VACCINE; METFORMIN; PARACETAMOL; RIBOFLAVIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABLATION THERAPY; ACID ASPIRATION; ALTITUDE; ANEMIA; ANXIETY DISORDER; APNEA; ASSISTED VENTILATION; ATELECTASIS; AUDIOLOGY; BODY WEIGHT GAIN; BRAIN DEPTH STIMULATION; BREATHING EXERCISE; CARDIOLOGY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CATARACT; CATARACT EXTRACTION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONSTIPATION; CONTRACTURE; DEPRESSION; DEVELOPMENTAL DELAY; DIABETES MELLITUS; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSPHAGIA; DYSTONIA; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAM; ELECTRORETINOGRAPHY; END STAGE RENAL DISEASE; EPILEPSY; FATIGUE; FETUS MONITORING; GLOMERULONEPHRITIS; HEADACHE; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH SURVEY; HEARING IMPAIRMENT; HEARING TEST; HEART ARRHYTHMIA; HEART DEATH; HEMODIALYSIS; HIP DISLOCATION; HUMAN; HYPOXIA; INTELLECTUAL IMPAIRMENT; INTENSIVE CARE; INTESTINAL DYSMOTILITY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LEBER HEREDITARY OPTIC NEUROPATHY; LIFESTYLE MODIFICATION; LIMB DEFORMITY; LIVER DISEASE; LUNG ALVEOLUS HYPOVENTILATION; MATERNAL CARE; MEDICAL SOCIETY; MELAS SYNDROME; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOPATHY; NEUROIMAGING; NEUROMUSCULAR DISEASE; NEUROPATHY; NUTRITIONAL SUPPORT; OBESITY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; ORTHOPEDIC SURGERY; OXYGEN THERAPY; PALLIATIVE THERAPY; PANCREAS DISEASE; PARENTERAL NUTRITION; PATIENT CARE; PEARSON SYNDROME; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE COMPLICATION; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PSEUDOOBSTRUCTION; REHABILITATION MEDICINE; REHYDRATION; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; SCOLIOSIS; SCREENING TEST; SIDEROBLASTIC ANEMIA; SLEEP DISORDER; SOCIAL SUPPORT; SPIROMETRY; STRABISMUS; STRABISMUS SURGERY; SUDDEN CARDIAC DEATH; SUPRAVENTRICULAR TACHYCARDIA; THORAX RADIOGRAPHY; VESTIBULOCOCHLEAR NERVE DISEASE; WOLFF PARKINSON WHITE SYNDROME; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; HEALTH CARE QUALITY;

DISEASE MANAGEMENT; HUMANS; MITOCHONDRIAL DISEASES; STANDARD OF CARE;

EID: 85030691854     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2017.107     Document Type: Review

References (95)

1. Parikh S, Goldstein A, Koenig MK, et al. Practice patterns of mitochondrial disease physicians in North America. Part 1: diagnostic and clinical challenges. Mitochondrion 2014;14:26–33.
2. Parikh S, Goldstein A, Koenig MK, et al. Practice patterns of mitochondrial disease physicians in North America. Part 2: treatment, care and management. Mitochondrion 2013;13:681–687.
3. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015;17:689–701.
4. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012:CD004426.
5. Pfeffer G, Horvath R, Klopstock T, et al. New treatments for mitochondrial disease—no time to drop our standards. Nat Rev Neurol 2013;9:474–481.
6. Turoff M, Linstone HA. The Delphi Method: Techniques and Applications. Addison-Wesley: Reading, MA, 1975.
7. Kullar PJ, Quail J, Lindsey P, et al. Both mitochondrial DNA and mitonuclear gene mutations cause hearing loss through cochlear dysfunction. Brain 2016;139:e33.
8. Santarelli R, Cama E, Scimemi P, et al. Reply: both mitochondrial DNA and mitonuclear gene mutations cause hearing loss through cochlear dysfunction. Brain 2016;139:e34.
9. Sue CM, Lipsett LJ, Crimmins DS, et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol 1998;43:350–359.
10. Wahbi K, Bougouin W, Behin A, et al. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. Eur Heart J 2015;36:2886–2893.
11. Bates MG, Bourke JP, Giordano C, d’Amati G, Turnbull DM, Taylor RW. Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J 2012;33:3023–3033.
12. El-Hattab AW, Scaglia F. Mitochondrial cardiomyopathies. Front Cardiovasc Med 2016;3:25.
13. Florian A, Ludwig A, Stubbe-Drager B, et al. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson 2015;17:40.
14. Brunel-Guitton C, Levtova A, Sasarman F. Mitochondrial diseases and cardiomyopathies. Can J Cardiol 2015;31:1360–1376.
15. Barends M, Verschuren L, Morava E, Nesbitt V, Turnbull D, McFarland R. Causes of death in adults with mitochondrial disease. JIMD Rep 2016;26: 103–113.
16. Rahman S, Hall AM. Mitochondrial disease—an important cause of end-stage renal failure. Pediatr Nephrol 2013;28:357–361.
17. Karaa A, Goldstein A. The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes. Pediatr Diabetes 2015;16:1–9.
18. El-Hattab AW, Emrick LT, Hsu JW, et al. Glucose metabolism derange-ments in adults with the MELAS m.3243A > G mutation. Mitochondrion 2014;18:63–69.
19. Mazzaccara C, Iafusco D, Liguori R, et al. Mitochondrial diabetes in children: seek and you will find it. PLoS One 2012;7:e34956.
20. Schaefer AM, Walker M, Turnbull DM, Taylor RW. Endocrine disorders in mitochondrial disease. Mol Cell Endocrinol 2013;379:2–11.
21. Chow J, Rahman J, Achermann JC, Dattani MT, Rahman S. Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol 2017;13:92–104.
22. Ng YS, Feeney C, Schaefer AM, et al. Pseudo-obstruction, stroke, and mitochondrial dysfunction: a lethal combination. Ann Neurol 2016;80:686–692.
23. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 1994;330:962–968.
24. Matsuzaki M, Izumi T, Shishikura K, Suzuki H, Hirayama Y. Hypothalamic growth hormone deficiency and supplementary GH therapy in two patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Neuropediatrics 2002;33:271–273.
25. Wilichowski E, Gruters A, Kruse K, et al. Hypoparathyroidism and deafness associated with pleioplasmic large scale rearrangements of the mitochondrial DNA: a clinical and molecular genetic study of four children with Kearns-Sayre syndrome. Pediatr Res 1997;41:193–200.
26. Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). GeneReviews. University of Washington: Seattle, WA, 1993.
27. Quade A, Zierz S, Klingmuller D. Endocrine abnormalities in mitochondrial myopathy with external ophthalmoplegia. Clin Investig 1992;70:396–402.
28. Rahman S. Gastrointestinal and hepatic manifestations of mitochondrial disorders. J Inherit Metab Dis 2013;36:659–673.
29. Rudolph CD, Hyman PE, Altschuler SM, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. J Pediatr Gastroenterol Nutr 1997;24:102–112.
30. Parsons T, Weimer L, Engelstad K, et al. Autonomic symptoms in carriers of the m.3243A > G mitochondrial DNA mutation. Arch Neurol 2010;67: 976–979.
31. Sekino Y, Inamori M, Yamada E, et al. Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases. World J Gastroenterol 2012;18:4557–4562.
32. Williams TB, Daniels M, Puthenveetil G, Chang R, Wang RY, Abdenur JE. Pearson syndrome: unique endocrine manifestations including neonatal diabetes and adrenal insufficiency. Mol Genet Metab 2012;106:104–107.
33. Verny C, Amati-Bonneau P, Letournel F, et al. Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis. Diabetes Metab 2008;34:620–626.
34. Staufner C, Haack TB, Kopke MG, et al. Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. J Inherit Metab Dis 2016;39:3–16.
35. Dimmock DP, Dunn JK, Feigenbaum A, et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transpl 2008;14:1480–1485.
36. Parikh S, Karaa A, Goldstein A, et al. Solid organ transplantation in primary mitochondrial disease: proceed with caution. Mol Genet Metab 2016;118:178–184.
37. McKiernan P, Ball S, Santra S, et al. Incidence of primary mitochondrial disease in children younger than 2 years presenting with acute liver failure. J Pediatr Gastroenterol Nutr 2016;63:592–597.
38. Finsterer J. Hematological manifestations of primary mitochondrial disorders. Acta Haematol 2007;118:88–98.
39. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656–2668.
40. Beier UH, Angelin A, Akimova T, et al. Essential role of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function and allograft survival. FASEB J 2015;29:2315–2326.
41. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol 2013;31:259–283.
42. Perl A, Gergely P Jr, Nagy G, Koncz A, Banki K. Mitochondrial hyper-polarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 2004;25:360–367.
43. Broomfield A, Sweeney MG, Woodward CE, et al. Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease. J Inherit Metab Dis 2015;38:445–457.
44. Ferreira C, Thompson R, Vernon H. Barth syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 1993.
45. Walker MA, Slate N, Alejos A, et al. Predisposition to infection and SIRS in mitochondrial disorders: 8 years’ experience in an academic center. J Allergy Clin Immunol Pract 2014;2:465–468, 468.e1.
46. Klein NP, Aukes L, Lee J, et al. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics 2011;127:e1139–46.
47. Shahni R, Cale CM, Anderson G, et al. Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. Brain 2015;138:2834–2846.
48. Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol 2012;27:539–550.
49. Martin-Hernandez E, Garcia-Silva MT, Vara J, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol 2005;20:1299–1305.
50. Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol 2012;54:397–406.
51. Debray FG, Lambert M, Chevalier I, et al. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics 2007;119:722–733.
52. Khurana DS, Salganicoff L, Melvin JJ, et al. Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies. Neuropediatrics 2008;39:8–13.
53. Lee HF, Chi CS, Tsai CR, Chen CH. Epileptic seizures in infants and children with mitochondrial diseases. Pediatr Neurol 2011;45:169–174.
54. Whittaker RG, Devine HE, Gorman GS, et al. Epilepsy in adults with mitochondrial disease: a cohort study. Ann Neurol 2015;78:949–957.
55. Bindoff LA, Engelsen BA. Mitochondrial diseases and epilepsy. Epilepsia 2012;53(suppl 4):92–97.
56. Besse A, Wu P, Bruni F, et al. The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab 2015;21:417–427.
57. Mirza NS, Alfirevic A, Jorgensen A, Marson AG, Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21:297–302.
58. DiMauro S, Hirano M. MELAS. In: Pagon RA, Adam MP, Ardinger HH, et al.(eds). GeneReviews. University of Washington: Seattle, WA, 1993.
59. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015;116:4–12.
60. Altmann J, Buchner B, Nadaj-Pakleza A, et al. Expanded phenotypic spectrum of the m.8344A > G “MERRF” mutation: data from the German mitoNET registry. J Neurol 2016;263:961–972.
61. Seremet OC, Barbuceanu F, Ionica FE, et al. Oral toxicity study of certain plant extracts containing pyrrolizidine alkaloids. Rom J Morphol Embryol 2016;57:1017–1023.
62. Martikainen MH, Ng YS, Gorman GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol 2016;73:668–674.
63. Tranchant C, Anheim M. Movement disorders in mitochondrial diseases. Rev Neurol (Paris) 2016;172:524–529.
64. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010;16:183–188.
65. Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 2006;59:859–862.
66. Hudson G, Chinnery PF. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet 2006;15(spec no 2):R244–52.
67. Girlanda P, Toscano A, Nicolosi C, et al. Electrophysiological study of neuromuscular system involvement in mitochondrial cytopathy. Clin Neurophysiol 1999;110:1284–1289.
68. Mancuso M, Piazza S, Volpi L, et al. Nerve and muscle involvement in mitochondrial disorders: an electrophysiological study. Neurol Sci 2012;33:449–452.
69. Luigetti M, Sauchelli D, Primiano G, et al. Mitochondrial neuropathy: considerations on pathogenesis. Eur J Neurol 2016;23:e55.
70. Mancuso M, Orsucci D, Angelini C, et al. “Mitochondrial neuropathies”: A survey from the large cohort of the Italian Network. Neuromuscul Disord 2016;26:272–276.
71. Menezes MP, Rahman S, Bhattacharya K, et al. Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. Mitochondrion 2016;30:162–167.
72. Koenig MK, Emrick L, Karaa A, et al. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. JAMA Neurol 2016;73:591–594.
73. Sofou K, De Coo IF, Isohanni P, et al. A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet J Rare Dis 2014;9:52.
74. Gronlund MA, Honarvar AK, Andersson S, et al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease. Br J Ophthalmol 2010;94:121–127.
75. Zhu CC, Traboulsi EI, Parikh S. Ophthalmological findings in 74 patients with mitochondrial disease. Ophthalmic Genet 2017;38:67–69.
76. Yu-Wai-Man P, Chinnery PF. Leber hereditary optic neuropathy. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds). GeneReviews. University of Washington: Seattle, WA, 1993.
77. Klopstock T, Metz G, Yu-Wai-Man P, et al. Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy. Brain 2013;136:e230.
78. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 2011;134:2677–2686.
79. Annaiah TK, Kodakkattil S, Sriemevan A. Pregnancy with mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS syn-drome) leading to confusion in the diagnosis of pulmonary embolism. J Obstet Gynaecol 2007;27:618–619.
80. Moriarty KT, McFarland R, Whittaker R, et al. Pre-eclampsia and magnesium toxicity with therapeutic plasma level in a woman with m.3243A > G MELAS mutation. J Obstet Gynaecol 2008;28:349.
81. Kokawa N, Ishii Y, Yamoto M, Nakano R. Pregnancy and delivery complicated by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Obstet Gynecol 1998;91:865.
82. Yanagawa T, Sakaguchi H, Nakao T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with deterioration during pregnancy. Intern Med 1998;37:780–783.
83. Kovilam OP, Cahill W, Siddiqi TA. Pregnancy with mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome. Obstet Gynecol 1999;93:853.
84. de Laat P, Fleuren LH, Bekker MN, Smeitink JA, Janssen MC. Obstetric complications in carriers of the m.3243A > G mutation, a retrospective cohort study on maternal and fetal outcome. Mitochondrion 2015;25: 98–103.
85. Riley LG, Rudinger-Thirion J, Schmitz-Abe K, et al. LARS2 variants associated with hydrops, lactic acidosis, sideroblastic anemia, and multisystem failure. JIMD Rep 2016;28:49–57.
86. Mancuso M, Orsucci D, Ienco EC, Pini E, Choub A, Siciliano G. Psychiatric involvement in adult patients with mitochondrial disease. Neurol Sci 2013;34:71–74.
87. Fattal O, Link J, Quinn K, Cohen BH, Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007;12:429–438.
88. Inczedy-Farkas G, Remenyi V, Gal A, et al. Psychiatric symptoms of patients with primary mitochondrial DNA disorders. Behav Brain Funct 2012;8:9.
89. Byrne E, Dennett X, Trounce I, Burdon J. Mitochondrial myoneuropathy with respiratory failure and myoclonic epilepsy. A case report with biochemical studies. J Neurol Sci 1985;71:273–281.
90. Cros D, Palliyath S, DiMauro S, Ramirez C, Shamsnia M, Wizer B. Respiratory failure revealing mitochondrial myopathy in adults. Chest 1992;101:824–828.
91. Wolfe LF, Joyce NC, McDonald CM, Benditt JO, Finder J. Management of pulmonary complications in neuromuscular disease. Phys Med Rehabil Clin N Am 2012;23:829–853.
92. Ramezani RJ, Stacpoole PW. Sleep disorders associated with primary mitochondrial diseases. J Clin Sleep Med 2014;10:1233–1239.
93. Luo Y, Yang X, Gao Y. Mitochondrial DNA response to high altitude: a new perspective on high-altitude adaptation. Mitochondrial DNA 2013;24:313–319.
94. Hoppeler H, Vogt M, Weibel ER, Fluck M. Response of skeletal muscle mitochondria to hypoxia. Exp Physiol 2003;88:109–119.
95. Murray AJ, Horscroft JA. Mitochondrial function at extreme high altitude. J Physiol 2016;594:1137–1149.